Reports Q2 revenue $303k vs 201k last year. “Our strong growth for the quarter demonstrates the success of our overall strategy for driving greater adoption of our flagship animal osteoarthritis veterinary medical device, Spryng with OsteoCushion Technology,” commented PetVivo (PETV) CEO, John Lai. “This record performance for a second fiscal quarter also reflects the increasing awareness of PrecisePRP(TM) for the treatment of osteoarthritis in animals that can be administered alongside Spryng.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PETV: